EUVIMEDEUVIMED entdecken
Leserbrief

Is There an Association Between GLP ‐ 1RA Use and Blood Cancer Incidence or Progression?

Hagop Kantarjian iD, Ayalew Tefferi iD

American Journal of Hematology · 13.11.2026

DOI: 10.1002/ajh.70552 ↗

Kurz gefasst

Leserbrief in der Zeitschrift American Journal of Hematology, online erschienen am 13.11.2026. Verfasst von Hagop Kantarjian und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA. Die Arbeit nennt 41 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

GLP‐1 receptor agonistsleukemialymphomamyelodysplasticmyelomamyeloproliferative

Autor:innen und Institutionen

  • Department of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.
  • Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.

ORCID-Profile: Hagop Kantarjian, Ayalew Tefferi

Zitieren

APA

Kantarjian, H., & Tefferi, A. (2026). Is There an Association Between GLP ‐ 1RA Use and Blood Cancer Incidence or Progression?. American Journal of Hematology. https://doi.org/10.1002/ajh.70552

Vancouver

Kantarjian H, Tefferi A. Is There an Association Between GLP ‐ 1RA Use and Blood Cancer Incidence or Progression?. American Journal of Hematology. 2026. doi:10.1002/ajh.70552

BibTeX
@article{Kantarjian2026,
  author = {Kantarjian, Hagop and Tefferi, Ayalew},
  title = {Is There an Association Between GLP ‐ 1RA Use and Blood Cancer Incidence or Progression?},
  journal = {American Journal of Hematology},
  year = {2026},
  doi = {10.1002/ajh.70552}
}
Kostenlos starten →